Form 4 for LAB STANDARD BIOTOOLS INC.
Accepted 2025-03-24 00:00:00 ET · period of report 2025-03-21 · accession 0000950170-25-044008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-24 | 2025-03-21 | LAB | Egholm Michael | Pres, CEO, Dir | A - Grant | $0.00 | +1.19M | 2.64M | +82% | $0 |
| D | 2025-03-24 | 2025-03-21 | LAB | Egholm Michael | Pres, CEO, Dir | A - Grant | $0.00 | +1.78M | 1.78M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-21 | A | A | 1,188,333 | $0.00 | 2,636,006 | D | — | — | (F1) Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2025 and the remaining RSUs vesting in equally quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. |
| 2 | Derivative | Stock Option (Right to buy) | 2025-03-21 | A | A | 1,782,500 | $0.00 | 1,782,500 | D | $1.21 · — to 2035-03-21 | 1,782,500 Common Stock | (F2) The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2025, with the remaining shares vesting in equally quarterly installments, thereafter, subject to the Reporting Person's continued service through the applicable vesting date. |